Letter to the Editor: “Lymphocyte‐Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis” | Synapse
Letter to the Editor: “Lymphocyte‐Monocyte Ratio Predicts Survival in Patients With Unresectable Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab: A Multicenter Analysis”
The aim is to investigate the relationship between the lymphocyte-monocyte ratio and survival in patients with unresectable hepatocellular carcinoma treated with durvalumab and tremelimumab.
Analyzed clinical outcomes in patients treated with durvalumab and tremelimumab.
Measured lymphocyte-monocyte ratio before treatment.
Evaluated patient survival rates based on the lymphocyte-monocyte ratio.
Higher lymphocyte-monocyte ratios are associated with improved survival rates.
Patients with lower ratios had shorter survival times.
The lymphocyte-monocyte ratio serves as a potential prognostic biomarker.
Abstract
Data sharing is not applicable to this article since no datasets were generated or analysed during the present study.